a6814785.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 10-Q

[ x ]
Quarterly Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended June 30, 2011
or
[    ]
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Transition Period from    to

 
Commission File Number 0-10763
 
Atrion Corporation
(Exact Name of Registrant as Specified in its Charter)
 
Delaware
 
63-0821819
(State or Other Jurisdiction of
Incorporation or Organization)
 
(I.R.S. Employer
Identification No.)
 
One Allentown Parkway, Allen, Texas  75002
(Address of Principal Executive Offices)        (Zip Code)
 
(972) 390-9800
(Registrant’s Telephone Number, Including Area Code)

Indicate by check whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  x Yes           o No

Indicate by check whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “accelerated filer.” “large accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (Check one):
 
Large accelerated filer o Accelerated filer x Non-accelerated filer o Smaller reporting company o
 
Indicate by check whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  o Yes           x No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

 
Title of Each Class
 
Number of Shares Outstanding at
July 11, 2011
Common stock, Par Value $0.10 per share
 
2,024,089

 
 
 

 

ATRION CORPORATION AND SUBSIDIARIES


TABLE OF CONTENTS
 

 
PART I.   Financial Information 2
       
 
Item 1.
Financial Statements
 
       
     
    For the Three and Six months Ended  
    June 30, 2011 and 2010 3
       
    Consolidated Balance Sheets (Unaudited)  
 
 
June 30, 2011 and December 31, 2010 4
       
    Consolidated Statements of Cash Flows (Unaudited)  
    For the Six months Ended  
    June 30, 2011 and 2010 5
       
    6
       
   
    Financial Condition and Results of Operations 8
       
 
13
       
 
13
       
PART II.   Other Information 13
       
 
13
       
  Item 1A. Risk Factors 13
       
 
14
       
15
       
16

 
1

 
 
 
 

 
PART I


FINANCIAL INFORMATION
 
 
 

 
 
2

 

 
Item 1.   Financial Statements
 
ATRION CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
 
    Three Months Ended     Six Months Ended  
   
June 30,
   
June 30,
 
   
2011
   
2010
   
2011
   
2010
 
   
(in thousands, except per share amounts)
 
       
Revenues
  $ 31,139     $ 27,881     $ 61,728     $ 54,782  
Cost of goods sold
    14,684       14,851       29,721       29,727  
Gross profit
    16,455       13,030       32,007       25,055  
                                 
Operating expenses:
                               
Selling
    1,341       1,346       2,836       2,764  
General and administrative
    3,949       2,829       7,333       5,783  
Research and development
    728       675       1,305       1,290  
      6,018       4,850       11,474       9,837  
Operating income
    10,437       8,180       20,533       15,218  
                                 
Interest income
    342       213       668       374  
Other income
    --       --       2       1  
      342       213       670       375  
                                 
Income before provision for income taxes
    10,779       8,393       21,203       15,593  
Provision for income taxes
    (3,760 )     (2,962 )     (7,326 )     (5,464 )
                                 
Net Income
  $ 7,019     $ 5,431     $ 13,877     $ 10,129  
                                 
Income per basic share
  $ 3.48     $ 2.69     $ 6.88     $ 5.01  
Weighted average basic shares outstanding
    2,019       2,022       2,018       2,020  
                                 
                                 
Income per diluted share
  $ 3.46     $ 2.67     $ 6.84     $ 4.98  
Weighted average diluted shares outstanding
    2,030       2,033       2,030       2,032  
                                 
Dividends per common share
  $ 0.42     $ 0.36     $ 0.84     $ 6.72  
 

The accompanying notes are an integral part of these statements.
 
 
3

 
 
ATRION CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Unaudited)
 
   
June 30,
   
December 31,
 
   
2011
   
2010
 
Assets
  (in thousands)  
             
Current assets:            
Cash and cash equivalents
  $ 9,744     $ 10,670  
Short-term investments
    19,166       10,715  
Accounts receivable
    14,835       11,521  
Inventories
    21,088       17,400  
Prepaid expenses
    2,780       1,050  
Deferred income taxes
    625       625  
      68,238       51,981  
                 
Long-term investments
    18,742       20,291  
                 
Property, plant and equipment
    108,810       103,789  
Less accumulated depreciation and amortization
    55,676       53,125  
      53,134       50,664  
                 
Other assets and deferred charges:                
Patents
    1,135       1,249  
Goodwill
    9,730       9,730  
Other
    779       737  
      11,644       11,716  
                 
    $ 151,758     $ 134,652  
                 
                 
Liabilities and Stockholders’ Equity                
                 
Current liabilities:                
Accounts payable and accrued liabilities
  $ 9,938     $ 7,200  
Accrued income and other taxes
    807       552  
      10,745       7,752  
                 
Line of credit
    --       --  
                 
Other non-current liabilities
    11,736       10,283  
                 
Stockholders’ equity:                
Common shares, par value $0.10 per share; authorized                
10,000 shares, issued 3,420 shares
    342       342  
Paid-in capital
    24,805       24,331  
Retained earnings
    143,453       131,286  
Treasury shares,1,396 at June 30, 2011 and 1,404                
at December 31, 2010, at cost
    (39,323     (39,342
Total stockholders’ equity
    129,277       116,617  
                 
                 
    $ 151,758     $ 134,652  
 
The accompanying notes are an integral part of these financial statements.
 
 
4

 
 
ATRION CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
 
    Six Months Ended  
   
June 30,
 
   
2011
   
2010
 
    (in thousands)  
Cash flows from operating activities:            
Net income
  $ 13,877     $ 10,129  
Adjustments to reconcile net income to                
net cash provided by operating activities:                
Depreciation and amortization
    3,163       3,884  
Deferred income taxes
    1,395       (197
Stock-based compensation
    461       323  
      18,896       14,139  
                 
Changes in operating assets and liabilities:                
Accounts receivable
    (3,314     (778
Inventories
    (3,688     507  
Prepaid expenses
    (1,730     (435
Other non-current assets
    18       (159
Accounts payable and accrued liabilities
    2,738       244  
Accrued income and other taxes
    255       1,555  
Other non-current liabilities
    58       10  
      13,233       15,083  
                 
Cash flows from investing activities:                
Property, plant and equipment additions
    (5,519     (1,806
Purchase of investments
    (9,723     (19,373
Proceeds from maturities of investments
    2,400       3,000  
Net change in accrued interest on investments
    361       (130
      (12,481     (18,309
                 
Cash flows from financing activities:                
Exercise of stock options
    --       343  
Shares tendered for employees’ taxes on stock-based                 
compensation
    --       (501
Tax benefit related to stock options
    19       1,060  
Dividends paid
    (1,697     (13,584
      (1,678     (12,682
                 
Net change in cash and cash equivalents
    (926     (15,908
Cash and cash equivalents at beginning of period
    10,670       20,694  
Cash and cash equivalents at end of period
  $ 9,744     $ 4,786  
                 
                 
                 
Cash paid for:                
Income taxes
  $ 6,893     $ 3,027  
 
The accompanying notes are an integral part of these financial statements.
 
 
5

 
 
ATRION CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
 
 
(1)           Basis of Presentation
 
The accompanying unaudited consolidated financial statements of Atrion Corporation and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and notes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, these statements include all adjustments necessary to present a fair statement of our consolidated results of operations, financial position and cash flows. Operating results for any interim period are not necessarily indicative of the results that may be expected for the full year. Preparation of the Company’s financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts in the financial statements and notes. Actual results could differ from those estimates. This Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and notes included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2010 ("2010 Form 10-K").  References herein to "Atrion," the "Company," "we," "our," and "us" refer to Atrion Corporation and its subsidiaries.

(2)           Inventories
 
Inventories are stated at the lower of cost or market. Cost is determined by using the first-in, first-out method. The following table details the major components of inventories (in thousands):
 
   
June 30,
   
December 31,
 
   
2011
   
2010
 
Raw materials
  $ 9,065     $ 7,888  
Work in process
    4,871       3,985  
Finished goods
    7,152       5,527  
Total inventories
  $ 21,088     $ 17,400  

(3)           Income per share
 
The following is the computation for basic and diluted income per share:

    Three months ended     Six months ended  
 
 
June, 30
   
June 30,
 
 
 
2011
   
2010
   
2011
   
2010
 
 
 
(in thousands, except per share amounts)
 
Net income
  $ 7,019     $ 5,431     $ 13,877     $ 10,129  
                                 
Weighted average basic shares outstanding
    2,019       2,022       2,018       2,020  
Add:  Effect of dilutive securities
    11       11       12       12  
Weighted average diluted shares outstanding
    2,030       2,033       2,030       2,032  
 

Earnings per share:
                       
Basic
  $ 3.48     $ 2.69     $ 6.88     $ 5.01  
Diluted
  $ 3.46     $ 2.67     $ 6.84     $ 4.98  
 
 
6

 
 
ATRION CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
 
 
Incremental shares from stock options, unvested restricted stock, restricted stock units and deferred stock units were included in the calculation of weighted average diluted shares outstanding using the treasury stock method. Dilutive securities representing 6,322 shares of common stock for the three and six month periods ended June 30, 2011 and dilutive securities representing 35 shares of common stock for the three and six month periods ended June 30, 2010 were excluded from the computation of weighted average diluted shares outstanding because their effect would have been anti-dilutive.

(5)           Investments
 
As of June 30, 2011, we held certain investments that are required to be measured for disclosure purposes at fair value on a recurring basis. These investments are considered Level 2 investments. We consider as current assets those investments which will mature in the next 12 months. The remaining investments are considered non-current assets. The amortized cost and fair value of our investments that are being accounted for as held-to-maturity securities, and the related gross unrealized gains and losses, were as follows as of June 30, 2011 ( in thousands):

         
Gross Unrealized
       
   
Cost
   
Gains
   
Losses
   
Fair Value
 
Short-term Investments:
                       
Corporate bonds
  $ 19,166     $ 214     $     $ 19,380  
                                 
Long-term Investments:
                               
Corporate bonds
  $ 18,742     $ 466     $     $ 19,208  

At June 30, 2011, the length of time until maturity of these securities ranged from two to 36 months.

(6)           Income Taxes
 
Our effective tax rate for the second quarter of 2011 was 34.9 percent, compared with 35.3 percent for the second quarter of 2010. The decrease in the effective tax rate for the 2011 period is primarily a result of the absence of tax incentives for research and development, or R&D, expenditures in the 2010 period.
 
(7)           Recent Accounting Pronouncements

From time to time, new accounting standards updates applicable to us are issued by the Financial Accounting Standards Board or, FASB, which we will adopt as of the specified effective date. Unless otherwise discussed, we believe the impact of recently issued standards updates that are not yet effective will not have a material impact on our consolidated financial statements upon adoption.

 
7

 
 
Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

We develop and manufacture products primarily for medical applications. We market components to other equipment manufacturers for incorporation in their products and sell finished devices to physicians, hospitals, clinics and other treatment centers. Our medical products primarily serve the fluid delivery, cardiovascular, and ophthalmology markets. Our other medical and non-medical products include instrumentation and disposables used in dialysis, and valves and inflation devices used in marine and aviation safety products.
 
Our products are used in a wide variety of applications by numerous customers. We encounter competition in all of our markets and compete primarily on the basis of product quality, price, engineering, customer service and delivery time.
 
Our strategy is to provide a broad selection of products in the areas of our expertise. R&D efforts are focused on improving current products and developing highly-engineered products that meet customer needs and have the potential for broad market applications and significant sales. Proposed new products may be subject to regulatory clearance or approval prior to commercialization and the time period for introducing a new product to the marketplace can be unpredictable. We also focus on controlling costs by investing in modern manufacturing technologies and controlling purchasing processes. We have been successful in consistently generating cash from operations and have used that cash to reduce indebtedness, to fund capital expenditures, to repurchase stock and to pay dividends.
 
Our strategic objective is to further enhance our position in our served markets by:
 
Focusing on customer needs;
Expanding existing product lines and developing new products;
Maintaining a culture of controlling cost; and
Preserving and fostering a collaborative, entrepreneurial management structure.
 
For the three months ended June 30, 2011, we reported revenues of $31.1 million, operating income of $10.4 million and net income of $7.0 million, up 12 percent, 28 percent and 29 percent, respectively, from the three months ended June 30, 2010. For the six months ended June 30, 2011, we reported revenues of $61.7 million, operating income of $20.5 million and net income of $13.9 million, up 13 percent, 35 percent and 37 percent, respectively, from the six months ended June 30, 2010.
 
Results for the three months ended June 30, 2011

Consolidated net income totaled $7.0 million, or $3.48 per basic and $3.46 per diluted share, in the second quarter of 2011. This is compared with consolidated net income of $5.4 million, or $2.69 per basic and $2.67 per diluted share, in the second quarter of 2010. The income per basic share computations are based on weighted average basic shares outstanding of 2,019,320 in the 2011 period and 2,021,755 in the 2010 period. The income per diluted share computations are based on weighted average diluted shares outstanding of 2,030,402 in the 2011 period and 2,032,961 in the 2010 period.

 
8

 
 
Consolidated revenues of $31.1 million for the second quarter of 2011 were 12 percent higher than revenues of $27.9 million for the second quarter of 2010. This increase was generally attributable to higher sales volumes and increased prices.

Revenues by product line were as follows (in thousands):

    Three Months ended  
   
June 30,
 
   
2011
   
2010
 
             
Fluid Delivery
  $ 12,490     $ 10,728  
Cardiovascular
    8,222       7,836  
Ophthalmology
    5,407       4,507  
Other
    5,020       4,810  
Total
  $ 31,139     $ 27,881  


Cost of goods sold of $14.7 million for the second quarter of 2011 was $167,000 lower than in the comparable 2010 period. Our cost of goods sold in the second quarter of 2011 was 47.2 percent of revenues compared with 53.3 percent of revenues in the second quarter of 2010. The primary contributors to this improvement were favorable product mix, the impact of continued cost improvement initiatives and favorable operational efficiencies.

Gross profit of $16.5 million in the second quarter of 2011 was $3.4 million, or 26 percent, higher than in the comparable 2010 period. Our gross profit percentage in the second quarter of 2011 was 52.8 percent of revenues compared with 46.7 percent of revenues in the second quarter of 2010. The increase in gross profit percentage in the 2011 period compared to the 2010 period was primarily related to favorable product mix, cost improvement initiatives and favorable operational efficiencies.

Our second quarter 2011 operating expenses of $6.0 million were $1.2 million higher than the operating expenses for the second quarter of 2010. This increase was comprised of a $1.1 million increase in General and Administrative, or G&A, expenses and a $53,000 increase in R&D expenses partially offset by a $5,000 decrease in Selling expenses. The increase in G&A expenses for the second quarter of 2011 was principally attributable to increased outside services and increased compensation. The increase in R&D expenses for the second quarter of 2011 was primarily related to increased outside services and compensation partially offset by decreased supplies.

Operating income in the second quarter of 2011 increased $2.3 million to $10.4 million, a 28 percent increase over operating income in the quarter ended June 30, 2010. Operating income was 34 percent of revenues in the second quarter of 2011 compared to 29 percent of revenues in the second quarter of 2010. The major contributor to the operating income improvement in the second quarter of 2011 was the previously mentioned increase in gross profit partially offset by the increase in operating expenses.

 
9

 
 
Income tax expense for the second quarter of 2011 was $3.8 million compared to income tax expense of $3.0 million for the same period in the prior year. The effective tax rate for the second quarter of 2011 was 34.9 percent, compared with 35.3 percent for the second quarter of 2010. The decrease in the effective tax rate for the 2011 period was primarily a result of the reinstatement in December 2010 of the federal tax credit for R&D expenditures. We expect the effective tax rate for the remainder of 2011 to be within a range of 34.0 to 35.0 percent.

Results for the six months ended June 30, 2011

Consolidated net income totaled $13.9 million, or $6.88 per basic and $6.84 per diluted share, in the first six months of 2011. This is compared with consolidated net income of $10.1 million, or $5.01 per basic and $4.98 per diluted share, in the first six months of 2010.  The income per basic share computations are based on weighted average basic shares outstanding of 2,017,759 in the 2011 period and 2,020,116 in the 2010 period. The income per diluted share computations are based on weighted average diluted shares outstanding of 2,029,993 in the 2011 period and 2,031,614 in the 2010 period.

Consolidated revenues of $61.7 million for the first six months of 2011 were 13 percent higher than revenues of $54.8 million for the first six months of 2010. This increase was generally attributable to higher sales volumes.

Revenues by product line were as follows (in thousands):

    Six Months ended  
   
June 30,
 
   
2011
   
2010
 
             
Fluid Delivery
  $ 24,217     $ 20,283  
Cardiovascular
    16,631       16,037  
Ophthalmology
    10,951       8,971  
Other
    9,929       9,491  
Total
  $ 61,728     $ 54,782  
 
Cost of goods sold of $29.7 million for the first six months of 2011 was $6,000 lower than in the comparable 2010 period. Our cost of goods sold in the first six months of 2011 was 48.1 percent of revenues compared with 54.3 percent of revenues in the first six months of 2010. The primary contributors to this improvement were favorable product mix, the impact of continued cost improvement initiatives and favorable operational efficiencies.

Gross profit of $32.0 million in the first six months of 2011 was $7.0 million, or 28 percent, higher than in the comparable 2010 period. Our gross profit percentage in the first six months of 2011 was 51.9 percent of revenues compared with 45.7 percent of revenues in the first six months of 2009. The increase in gross profit percentage in the 2011 period compared to the 2010 period was primarily related to favorable product mix, cost improvement initiatives and favorable operational efficiencies.

Our operating expenses for the first six months of 2011 of $11.5 million were $1.6 million higher than the operating expenses for the first six months of 2010. This increase was comprised of a $1.6 million increase in G&A expenses, a $72,000 increase in Selling expenses and a $15,000 increase in R&D expenses. The increase in G&A expenses for the first six months of 2011 was principally attributable to increased compensation and increased outside services. The increase in Selling expenses for the first six months of 2011 was primarily related to outside services. The increase in R&D costs was primarily related to increased compensation partially offset by reduced supplies.

 
10

 
 
Operating income in the first six months of 2011 increased $5.3 million to $20.5 million, a 35 percent increase over operating income in the six months ended June 30, 2010. Operating income was 33 percent of revenues in the first six months of 2011 compared to 28 percent of revenues in the first six months of 2010. The major contributor to the operating income improvement in the first six months of 2011 was the previously mentioned increase in gross profit.

Interest income for the six months ended June 30, 2011 increased $294,000 over the same period in 2010 primarily as a result of increased levels of investments. Income tax expense for the first six months of 2011 was $7.3 million compared to income tax expense of $5.5 million for the same period in the prior year. The effective tax rate for the first six months of 2011 was 34.6 percent, compared with 35.0 percent for the first six months of 2010. The decrease in the effective tax rate for the 2011 period is primarily a result of the absence of tax incentives for R&D expenditures in 2010.
 
Liquidity and Capital Resources
 
We have a $25.0 million revolving credit facility with a money center bank to be utilized for the funding of operations and for major capital projects or acquisitions, subject to certain limitations and restrictions. Borrowings under the credit facility bear interest that is payable monthly at 30-day, 60-day or 90-day LIBOR, as selected by us, plus one percent. We had no outstanding borrowings under our credit facility at June 30, 2011 or at December 31, 2010. The credit facility, which expires November 12, 2012, and may be extended under certain circumstances, contains various restrictive covenants, none of which is expected to impact our liquidity or capital resources. At June 30, 2011, we were in compliance with all financial covenants and had $25.0 million available for borrowing under the credit facility. We believe that the bank providing the credit facility is highly-rated and that the entire $25.0 million under the credit facility is currently available to us. If that bank were unable to provide such funds, we believe that such inability would not impact our ability to fund operations.

At June 30, 2011, we had $47.7 million in cash and cash equivalents and short-term and long-term investments, an increase of $6.0 million from December 31, 2010. The principal contributor to this increase was the cash generated by operating activities.

As of June 30, 2011, we had working capital of $57.5 million, including $9.7 million in cash and cash equivalents and $19.2 million in short-term investments. The $13.3 million increase in working capital during the first six months of 2011 was primarily related to increases in short-term investments, receivables and inventories partially offset by increases in accounts payable and accrued liabilities. The increase in short-term investments is primarily related to purchases of short-term bonds. The increase in accounts receivable was primarily related to the increase in revenues for the second quarter of 2011 as compared with the fourth quarter of 2010. The change in inventories is related to increased stocking levels necessary to support current operations. In addition, the Company began purchasing critical raw material in large volumes to hedge against future price increases and take advantage of volume discounts.  The increase in accounts payable and accrued liabilities was primarily related to increased inventory levels.

 
11

 
 
Cash flows from operating activities generated $13.2 million for the six months ended June 30, 2011 as compared to $15.1 million for the six months ended June 30, 2010. The decrease in the 2011 period was primarily attributable to increased cash requirements for working capital items for the 2011 period partially offset by increased operational results as compared to the 2010 period. During the first six months of 2011, we expended $5.5 million for the addition of property and equipment, $3.6 million of which was spent in the 2011 second quarter. Maturities of investments generated $2.4 million during the first six months of 2011. We expended $9.7 million for the purchase of investments and we paid dividends of $1.7 million during the first six months of 2011.

We believe that our $47.7 million in cash, cash equivalents, short-term investments and long-term investments, along with cash flows from operations and available borrowings of up to $25.0 million under our credit facility will be sufficient to fund our cash requirements for at least the foreseeable future. We believe that our strong financial position would allow us to access equity or debt financing should that be necessary and our capital resources should not be materially impacted by the current economic environment. Additionally, we believe that our cash and cash equivalents, short-term investments and long-term investments, as a whole, will continue to increase during the remainder of 2011.

Forward-Looking Statements
 
Statements in this Management’s Discussion and Analysis and elsewhere in this Quarterly Report on Form 10-Q that are forward-looking are based upon current expectations, and actual results or future events may differ materially. Therefore, the inclusion of such forward-looking information should not be regarded as a representation by us that our objectives or plans will be achieved. Such statements include, but are not limited to, our effective tax rate for the remainder of 2011, our ability to fund our cash requirements for the foreseeable future with our current assets, long-term investments, cash flow and borrowings under the credit facility, the impact that the inability of the bank providing the credit facility to provide funds thereunder would have on our ability to fund operations, our access to equity and debt financing, the impact of the current economic environment on our capital resources and the increase in cash, cash equivalents, and investments during the remainder of 2011. Words such as “expects,” “believes,” “anticipates,” “intends,” “should,” “plans,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements contained herein involve numerous risks and uncertainties, and there are a number of factors that could cause actual results or future events to differ materially, including, but not limited to, the following: changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; the impact of competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; implementation of new manufacturing processes or implementation of new information systems; our ability to protect our intellectual property; changes in the prices of raw materials; changes in product mix; intellectual property and product  liability claims and product recalls; the ability to attract and retain qualified personnel; and the loss of, or any material reduction in sales to, any significant customers. In addition, assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic review which may cause us to alter our marketing, capital expenditures or other budgets, which in turn may affect our results of operations and financial condition.

 
12

 
 
Item 3.   Quantitative and Qualitative Disclosures About Market Risk
 
For the quarter ended June 30, 2011, we did not experience any material changes in market risk exposures that affect the quantitative and qualitative disclosures presented in our 2010 Form 10-K.
 
Item 4.   Controls and Procedures
 
Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of June 30, 2011. Based upon this evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective. There were no changes in our internal control over financial reporting for the quarter ended June 30, 2011 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.
 
 
PART II

OTHER INFORMATION
Item 1.   Legal Proceedings
 
From time to time, we may be involved in claims or litigation that arise in the normal course of business. We are not currently a party to any legal proceedings, which, if decided adversely, would have a material adverse effect on our business, financial condition, or results of operations.

Item 1A. Risk Factors
 
There were no material changes to the risk factors disclosed in our 2010 Form 10-K.
 
 
13

 
 
Item 6.   Exhibits
 
Exhibit
 
Number
Description
   
10.1
Amended and Restated Atrion Corporation 2006 Equity Incentive Plan (as last amended on May 26, 2011)
   
10.2
Form of Award Agreement for Incentive Stock Option Award under Amended and Restated Atrion Corporation 2006 Equity Incentive Plan
   
10.3
Form of Award Agreement for Non-Qualified Stock Option Award under Amended and Restated Atrion Corporation 2006 Equity Incentive Plan
   
10.4
Form of Award Agreement for Common Stock Award under Amended and Restated Atrion Corporation 2006 Equity Incentive Plan
   
10.5
Form of Award Agreement for Restricted Stock Award under Amended and Restated Atrion Corporation 2006 Equity Incentive Plan
   
10.6
Form of Award Agreement for Restricted Stock Units Award under Amended and Restated Atrion Corporation 2006 Equity Incentive Plan
   
31.1
Sarbanes-Oxley Act Section 302 Certification of Chief Executive Officer
   
31.2
Sarbanes-Oxley Act Section 302 Certification of Chief Financial Officer
   
32.1
Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes – Oxley Act Of 2002
   
32.2
Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes – Oxley Act Of 2002
   
 101.INS
XBRL Instance Document
   
 101.SCH
XBRL Taxonomy Extension Schema Document
   
 101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document
   
 101.DEF
XBRL Taxonomy Extension Definition Linkbase Document
   
 101.LAB
XBRL Taxonomy Extension Label Linkbase Document
   
 101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document
 
 
14

 
 
SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.




 
Atrion Corporation
 
(Registrant)
     
     
Date:  August 4, 2011
By:
/s/ David A. Battat
   
David A. Battat
   
President and Chief
   
Executive Officer
     
     
     
     
Date:  August 4, 2011
By:
/s/ Jeffery Strickland
   
Jeffery Strickland
   
Vice President and
   
Chief Financial Officer
   
(Principal Accounting and
   
Financial Officer)
 
 
15

 
 
Exhibit Index
 
Exhibit
 
Number
Description
   
10.1
Amended and Restated Atrion Corporation 2006 Equity Incentive Plan (as last amended on May 26, 2011)
   
10.2
Form of Award Agreement for Incentive Stock Option Award under Amended and Restated Atrion Corporation 2006 Equity Incentive Plan
   
10.3
Form of Award Agreement for Non-Qualified Stock Option Award under Amended and Restated Atrion Corporation 2006 Equity Incentive Plan
   
10.4
Form of Award Agreement for Common Stock Award under Amended and Restated Atrion Corporation 2006 Equity Incentive Plan
   
10.5
Form of Award Agreement for Restricted Stock Award under Amended and Restated Atrion Corporation 2006 Equity Incentive Plan
   
10.6
Form of Award Agreement for Restricted Stock Units Award under Amended and Restated Atrion Corporation 2006 Equity Incentive Plan
   
31.1
Sarbanes-Oxley Act Section 302 Certification of Chief Executive Officer
   
31.2
Sarbanes-Oxley Act Section 302 Certification of Chief Financial Officer
   
32.1
Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes – Oxley Act Of 2002
   
32.2
Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes – Oxley Act Of 2002
   
 101.INS
XBRL Instance Document
   
 101.SCH
XBRL Taxonomy Extension Schema Document
   
 101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document
   
 101.DEF
XBRL Taxonomy Extension Definition Linkbase Document
   
 101.LAB
XBRL Taxonomy Extension Label Linkbase Document
   
 101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document
 
 
16